The TH-07 therapeutic formula based on the combination of three molecules known for their effectiveness is developed and stabilized. This new formula presents a unique opportunity for the two Moncton scientists.

Phase II clinical trials are performed in Dieppe (NB) to prove the efficacy of the synergetic effect of three proprietary blend molecules in stopping hair loss, increasing regrowth and making the hair thicker and darker. The results are outstanding, and product performance is far superior to that of the leading products on the market.

Multiple international patent applications are filed. 

TH-07: International, Canada, China, USA, Europe, Macau, India

TH-16: Canada, USA, Europe, Hong Kong, China

Dr. Sekhavat and Dr. Ford have meetings with the U.S. Food and Drug Administration (FDA) and Health Canada with this proof of concept and are granted a Phase III approval and given a roadmap to market.

The FDA approves Triple Hair for a Phase III study under article 505(b) 2 conditional to a successful bioavailability study.

Dr. Asotra initiates the appropriate R&D workshops and regulatory work to establish a clear roadmap for the Phase III clinical trials greenlighted by the FDA and Health Canada. To this end, he sets up several working committees to guarantee reliable active ingredient sourcing, stability testing and pharmacokinetic testing.

Identification and meeting with potential pharma partners to accelerate the commercialization of TH-07 in major markets with unmet needs.

The Triple Hair team is set to initiate Phase III clinical trials in Canada and the United States for their TH-07 triple combination therapy. The trial will involve double-blinded, randomized, placebo-controlled, parallel-group tests, take place over a year and be conducted in multiple Canadian and U.S. sites.